Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses

This study has been terminated.

Sponsor:

Information provided by:

Wyeth is now a wholly owned subsidiary of Pfizer

ClinicalTrials.gov Identifier:

NCT00909688

First received: May 27, 2009

Last updated: October 7, 2009

Last verified: October 2009

Purpose

To determine the safety, tolerability, and drug absorption profile of multiple IV doses of BLI 489 in healthy subjects.

Condition	Intervention	Phase
Healthy	Drug: BLI-489 Drug: placebo	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver, Investigator)
Official Title:	Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:

Assess safety of drug given to healthy subjects by evaluating any reported adverse events (AEs), scheduled physical examinations, vital sign measurements, 12-lead ECGs, and clinical laboratory test results. [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	40
Study Start Date:	June 2009
Estimated Study Completion Date:	October 2009
Estimated Primary Completion Date:	October 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 BLI-489	Drug: BLI-489
Placebo Comparator: 2 placebo	Drug: placebo

Eligibility

Criteria

Inclusion Criteria:

Men or women of non-childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening;
Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight ≥50 kg.;
Healthy as determined by the investigator on the basis of screening evaluations;
Calculated creatinine clearance within normal limits using the Cockcroft-Gault formula;
Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history, and if a smoker must be able to abstain from smoking during the inpatient stay;
Have a high probability for compliance with and completion of the study.

Exclusion Criteria:

Presence or history of any disorder that may prevent the successful completion of the study;
Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease;
Any surgical or medical condition that may interfere with the distribution, metabolism, or excretion of the investigational product;
Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1;
History of drug abuse within 1 year before study day 1;
Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00909688

Locations

United States, Washington

Tacoma, Washington, United States, 98418

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

Study Director:

Medical Monitor

Wyeth is now a wholly owned subsidiary of Pfizer

More Information

No publications provided

Responsible Party:	Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier:	NCT00909688 History of Changes
Other Study ID Numbers:	3219K1-1001
Study First Received:	May 27, 2009
Last Updated:	October 7, 2009
Health Authority:	United States: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Healthy Subjects

ClinicalTrials.gov processed this record on June 18, 2013